Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$21.69 0.91 (4.38%) as of 4:30 Fri 5/31


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 6.73(B)
Last Volume: 3,013,019 Avg Vol: 2,434,266
52 Week Range: $18.78 - $24.13
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 17.5
Insider 6 Months    : 18.9
Insider 3/6 Months : 36.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 425,000 615,000 735,409 735,409
Total Buy Value $8,733,955 $12,666,689 $15,268,727 $15,268,727
Total People Bought 1 1 1 1
Total Buy Transactions 2 3 4 4
Total Shares Sold 80,531 241,700 593,372 1,012,962
Total Sell Value $1,755,807 $5,376,989 $12,725,795 $20,083,859
Total People Sold 5 7 9 12
Total Sell Transactions 5 10 16 27
End Date 2024-03-03 2023-12-01 2023-06-02 2022-06-02

   
Records found: 1428
  Page 14 of 58  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Senner Christopher J. EVP and CFO   •       –      –    2021-01-12 4 OE $3.66 $109,800 D/D 30,000 275,596     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-01-04 4 OE $1.90 $256,100 D/D 50,000 541,754     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-01-04 4 AS $20.32 $1,320,800 D/D (65,000) 283,124 24%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-01-04 4 OE $1.70 $110,500 D/D 65,000 348,124     -
   Morrissey Michael M President and CEO   •       •      –    2020-12-28 4 GD $0.00 $0 I/I 126,565 992,309     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2020-12-18 4 AS $20.01 $1,300,650 D/D (65,000) 283,124 23%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2020-12-18 4 OE $1.70 $110,500 D/D 65,000 348,124     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2020-12-17 4 GD $0.00 $0 D/D 2,500 491,754     -
   Willsey Lance Director   –       •      –    2020-12-04 4 OE $5.82 $617,746 D/D 106,142 474,415     -
   Marchesi Vincent T Director   –       •      –    2020-11-24 4 S $18.50 $740,074 D/D (40,004) 90,212 -27%     
   Marchesi Vincent T Director   –       •      –    2020-11-24 4 OE $5.82 $232,823 D/D 40,004 130,216     -
   Morrissey Michael M President and CEO   •       •      –    2020-11-20 4 GA $0.00 $0 I/I 187,239 1,118,874     -
   Morrissey Michael M President and CEO   •       •      –    2020-11-20 4 GD $0.00 $0 D/D 187,239 386,641     -
   Haley Patrick J. EVP, Commercial   •       –      –    2020-11-15 4 D $20.16 $210,591 D/D (10,446) 239,245     -
   Senner Christopher J. EVP and CFO   •       –      –    2020-11-15 4 D $20.16 $274,116 D/D (13,597) 245,596     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2020-11-15 4 D $20.16 $228,030 D/D (11,311) 283,124     -
   Morrissey Michael M President and CEO   •       •      –    2020-11-15 4 D $20.16 $503,073 D/D (24,954) 573,880     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2020-11-15 4 OE $7.27 $218,100 D/D 30,000 494,254     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2020-11-15 4 D $20.16 $206,862 D/D (10,261) 464,254     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2020-11-15 4 D $20.16 $301,452 D/D (14,953) 477,399     -
   Wyszomierski Jack L Director   –       •      –    2020-11-10 4 S $20.61 $700,740 D/D (34,000) 197,809 -7%     
   Wyszomierski Jack L Director   –       •      –    2020-11-10 4 OE $5.82 $363,185 D/D 62,403 231,809     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2020-10-22 4 D $21.79 $1,203,571 D/D (55,235) 491,835     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2020-10-22 4 A $0.00 $0 D/D 213,879 547,070     -
   Haley Patrick J. EVP, Commercial   •       –      –    2020-10-22 4 D $21.79 $962,769 D/D (44,184) 249,618     -
  1428 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 58
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us